{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-174943","form_type":"8-K","ticker":"PHAT","cik":"0001783183","company_name":"Phathom Pharmaceuticals, Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.976968+00:00","generated_at":"2026-05-17T18:03:19.201333+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Phathom Q2 revenue $39.5M, up from $7.3M YoY; 580k+ VOQUEZNA scripts filled","bullets":["Net revenues $39.5M in Q2 2025 vs $7.3M in Q2 2024; net loss $75.8M vs $91.4M YoY.","Over 580k total VOQUEZNA prescriptions filled (+49% since May 1); ~173k in Q2 (36% sequential growth).","10-year NCE exclusivity for VOQUEZNA 10mg/20mg tablets through May 2032; generic entry unlikely before 2033.","Full-year 2025 revenue guidance $165M-$175M; expects non-GAAP OpEx <$60M in Q3 and <$55M in Q4.","Appointed Anne Marie Cook as Chief Legal Officer and Corporate Secretary."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-174943","json":"https://secwatch.observer/filing/0001193125-25-174943.json","markdown":"https://secwatch.observer/filing/0001193125-25-174943.md","text":"https://secwatch.observer/filing/0001193125-25-174943.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783183/000119312525174943/0001193125-25-174943-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783183/000119312525174943/d907916d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T18:03:19.201333+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}